{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:36:33Z","timestamp":1792683393861,"version":"4.5.0"},"reference-count":101,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune disease of the central nervous system that causes recurrent attacks of optic neuritis, myelitis, and brainstem symptoms, resulting in severe neurological disability. Preventive treatment with immunosuppressive agents reduces relapse rate and improves long-term prognosis. In recent years, the potential therapeutical effect of new agents has been investigated. Two of these, the anti-interleukin 6 (IL-6) agents tocilizumab and satralizumab, have been studied in active NMOSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>To systematically review the current data regarding the efficacy and safety of anti-IL-6 agents in NMOSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result:<\/jats:title><jats:p>Fourteen case reports and 5 case series of intravenous tocilizumab have shown beneficial clinical and paraclinical effects compared to commonly used therapies, and another case series of subcutaneous tocilizumab has shown it is as effective as the IV formulation. A phase 2 comparative trial has shown tocilizumab IV to be more effective than azathioprine for relapse prevention. A phase 3 trial of subcutaneous satralizumab versus placebo, has shown a lower risk of relapse in the sartralizumab-treated group, both as add-on therapy to stable immunosuppressant and as monotherapy. Tocilizumab also reduced pain severity in two trials and fatigue scores in one trial, but satralizumab did not significantly improve pain and fatigue. Adverse events with both agents were relatively mild and comparable to placebo and azathioprine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The anti-Il-6 agents tocilizumab and satralizumab show promising results in active NMOSD. Further randomized, larger-scale trials are needed to better define the role of these agents in the growing arsenal of NMOSD treatments.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570159x18666200429010825","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T16:52:15Z","timestamp":1588179135000},"page":"220-232","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy"],"prefix":"10.2174","volume":"19","author":[{"given":"Itay","family":"Lotan","sequence":"first","affiliation":[{"name":"NYU Langone Health, Multiple Sclerosis Comprehensive Care Center, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"McGowan","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11882-016-0619-4","volume":"16","author":"Rosales D.","year":"2016","unstructured":"Rosales D.; Kister I.; Common and rare manifestations of neuromyelitis optica spectrum disorder. Curr Allergy Asthma Rep 2016,16(6),42","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"Weinshenker B.G.","year":"2017","unstructured":"Weinshenker B.G.; Wingerchuk D.M.; Neuromyelitis spectrum disorders. Mayo Clin Proc 2017,92(4),663-679","journal-title":"Mayo Clin Proc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"Wingerchuk D.M.","year":"1999","unstructured":"Wingerchuk D.M.; Hogancamp W.F.; O\u2019Brien P.C.; Weinshenker B.G.; The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999,53(5),1107-1114","journal-title":"Neurology"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/460825","volume":"2012","author":"Oh J.","year":"2012","unstructured":"Oh J.; Levy M.; Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012,2012","journal-title":"Neurol Res Int"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"Wingerchuk D.M.","year":"2007","unstructured":"Wingerchuk D.M.; Lennon V.A.; Lucchinetti C.F.; Pittock S.J.; Weinshenker B.G.; The spectrum of neuromyelitis optica. Lancet Neurol 2007,6(9),805-815","journal-title":"Lancet Neurol"},{"key":"ref=6","first-page":"1033","volume":"8","author":"Devic E.","year":"1894","unstructured":"Devic E.; My\u00e9lite subaigu\u00eb compliqu\u00e9e de n\u00e9vrite optique. Bull M\u00e9d 1894,8,1033","journal-title":"Bull M\u00e9d"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","volume":"10","author":"Jarius S.","year":"2013","unstructured":"Jarius S.; Wildemann B.; The history of neuromyelitis optica. J Neuroinflammation 2013,10(1),8","journal-title":"J Neuroinflammation"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0039-3399505","volume":"39","author":"Prasad S.","year":"2019","unstructured":"Prasad S.; Chen J.; What you need to know about AQP4, MOG, and NMOSD. Semin Neurol 2019,39(6),718-731","journal-title":"Semin Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"Lennon V.A.","year":"2004","unstructured":"Lennon V.A.; Wingerchuk D.M.; Kryzer T.J.; Pittock S.J.; Lucchinetti C.F.; Fujihara K.; Nakashima I.; Weinshenker B.G.; A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004,364(9451),2106-2112","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"Lennon V.A.","year":"2005","unstructured":"Lennon V.A.; Kryzer T.J.; Pittock S.J.; Verkman A.S.; Hinson S.R.; IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005,202(4),473-477","journal-title":"J Exp Med"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"Zamvil S.S.","year":"2015","unstructured":"Zamvil S.S.; Slavin A.J.; Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015,2(1)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"Hamid S.H.M.","year":"2017","unstructured":"Hamid S.H.M.; Whittam D.; Mutch K.; Linaker S.; Solomon T.; Das K.; Bhojak M.; Jacob A.; What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 2017,264(10),2088-2094","journal-title":"J Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"Jarius S.","year":"2016","unstructured":"Jarius S.; Ruprecht K.; Kleiter I.; Borisow N.; Asgari N.; Pitarokoili K.; Pache F.; Stich O.; Beume L.A.; H\u00fcmmert M.W.; Ringelstein M.; Trebst C.; Winkelmann A.; Schwarz A.; Buttmann M.; Zimmermann H.; Kuchling J.; Franciotta D.; Capobianco M.; Siebert E.; Lukas C.; Korporal-Kuhnke M.; Haas J.; Fechner K.; Brandt A.U.; Schanda K.; Aktas O.; Paul F.; Reindl M.; Wildemann B.; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016,13(1),280","journal-title":"J Neuroinflammation"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"Narayan R.","year":"2018","unstructured":"Narayan R.; Simpson A.; Fritsche K.; Salama S.; Pardo S.; Mealy M.; Paul F.; Levy M.; MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018,25,66-72","journal-title":"Mult Scler Relat Disord"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"Sato D.K.","year":"2014","unstructured":"Sato D.K.; Callegaro D.; Lana-Peixoto M.A.; Waters P.J.; de Haidar Jorge F.M.; Takahashi T.; Nakashima I.; Apostolos-Pereira S.L.; Talim N.; Simm R.F.; Lino A.M.; Misu T.; Leite M.I.; Aoki M.; Fujihara K.; Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014,82(6),474-481","journal-title":"Neurology"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418762083","volume":"11","author":"Weber M.S.","year":"2018","unstructured":"Weber M.S.; Derfuss T.; Metz I.; Br\u00fcck W.; Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disorder 2018,11","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.msard.2018.08.008","volume":"25","author":"Bensi C.","year":"2018","unstructured":"Bensi C.; Marrodan M.; Gonz\u00e1lez A.; Chertcoff A.; Osa Sanz E.; Chaves H.; Schteinschnaider A.; Correale J.; Farez M.F.; Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Mult Scler Relat Disord 2018,25,246-250","journal-title":"Mult Scler Relat Disord"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116430","volume":"405","author":"Chen C.","year":"2019","unstructured":"Chen C.; Liu C.; Fang L.; Zou Y.; Ruan H.; Wang Y.; Cui C.; Sun X.; Peng L.; Qiu W.; Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. J Neurol Sci 2019,405","journal-title":"J Neurol Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"Kitley J.","year":"2014","unstructured":"Kitley J.; Waters P.; Woodhall M.; Leite M.I.; Murchison A.; George J.; K\u00fcker W.; Chandratre S.; Vincent A.; Palace J.; Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014,71(3),276-283","journal-title":"JAMA Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12732","volume":"2","author":"Mariano R.","year":"2019","unstructured":"Mariano R.; Messina S.; Kumar K.; Kuker W.; Leite M.I.; Palace J.; Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw Open 2019,2(10)","journal-title":"JAMA Netw Open"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"Ramanathan S.","year":"2016","unstructured":"Ramanathan S.; Prelog K.; Barnes E.H.; Tantsis E.M.; Reddel S.W.; Henderson A.P.; Vucic S.; Gorman M.P.; Benson L.A.; Alper G.; Riney C.J.; Barnett M.; Parratt J.D.; Hardy T.A.; Leventer R.J.; Merheb V.; Nosadini M.; Fung V.S.; Brilot F.; Dale R.C.; Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2016,22(4),470-482","journal-title":"Mult Scler"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"Sep\u00falveda M.","year":"2016","unstructured":"Sep\u00falveda M.; Armangu\u00e9 T.; Sola-Valls N.; Arrambide G.; Meca-Lallana J.E.; Oreja-Guevara C.; Mendibe M.; Alvarez de Arcaya A.; Aladro Y.; Casanova B.; Olascoaga J.; Jim\u00e9nez-Huete A.; Fern\u00e1ndez-Fournier M.; Rami\u00f3-Torrent\u00e0 L.; Cobo-Calvo A.; Vi\u00f1als M.; de Andr\u00e9s C.; Meca-Lallana V.; Cervell\u00f3 A.; Calles C.; Rubio M.B.; Ramo-Tello C.; Caminero A.; Munteis E.; Antig\u00fcedad A.R.; Blanco Y.; Villoslada P.; Montalban X.; Graus F.; Saiz A.; Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016,3(3)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","volume":"90","author":"Hacohen Y.","year":"2018","unstructured":"Hacohen Y.; Palace J.; Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology 2018,90(21),947-948","journal-title":"Neurology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","volume":"9","author":"Borisow N.","year":"2018","unstructured":"Borisow N.; Mori M.; Kuwabara S.; Scheel M.; Paul F.; Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol 2018,9,888","journal-title":"Front Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"Jarius S.","year":"2018","unstructured":"Jarius S.; Paul F.; Aktas O.; Asgari N.; Dale R.C.; de Seze J.; Franciotta D.; Fujihara K.; Jacob A.; Kim H.J.; Kleiter I.; K\u00fcmpfel T.; Levy M.; Palace J.; Ruprecht K.; Saiz A.; Trebst C.; Weinshenker B.G.; Wildemann B.; MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018,15(1),134","journal-title":"J Neuroinflammation"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"Wingerchuk D.M.","year":"2015","unstructured":"Wingerchuk D.M.; Banwell B.; Bennett J.L.; Cabre P.; Carroll W.; Chitnis T.; de Seze J.; Fujihara K.; Greenberg B.; Jacob A.; Jarius S.; Lana-Peixoto M.; Levy M.; Simon J.H.; Tenembaum S.; Traboulsee A.L.; Waters P.; Wellik K.E.; Weinshenker B.G.; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015,85(2),177-189","journal-title":"Neurology"},{"key":"ref=27","first-page":"815","volume":"25","year":"2019","unstructured":"EP F Neuromyelitis optica spectrum disorder and other nonmultiple sclerosis central nervous system inflammatory diseases Continuum (Mineap Minn) 2019,25(3),815-844","journal-title":"EP F Neuromyelitis optica spectrum disorder and other nonmultiple sclerosis central nervous system inflammatory diseases Continuum (Mineap Minn)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","volume":"70","author":"Sato D.","year":"2012","unstructured":"Sato D.; Callegaro D.; Lana-Peixoto M.A.; Fujihara K.; Brazilian committee for treatment and research in multiple sclerosis. treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012,70(1),59-66","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","volume":"18","author":"Kessler R.A.","year":"2016","unstructured":"Kessler R.A.; Mealy M.A.; Levy M.; Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 2016,18(1),2","journal-title":"Curr Treat Options Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"Kimbrough D.J.","year":"2012","unstructured":"Kimbrough D.J.; Fujihara K.; Jacob A.; Lana-Peixoto M.A.; Leite M.I.; Levy M.; Marignier R.; Nakashima I.; Palace J.; de Seze J.; Stuve O.; Tenembaum S.N.; Traboulsee A.; Waubant E.; Weinshenker B.G.; Wingerchuk D.M.; GJCF-CC","journal-title":"Mult Scler Relat Disord"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"Stellmann J.P.","year":"2017","unstructured":"Stellmann J.P.; Krumbholz M.; Friede T.; Gahlen A.; Borisow N.; Fischer K.; Hellwig K.; Pache F.; Ruprecht K.; Havla J.; K\u00fcmpfel T.; Aktas O.; Hartung H.P.; Ringelstein M.; Geis C.; Kleinschnitz C.; Berthele A.; Hemmer B.; Angstwurm K.; Young K.L.; Schuster S.; Stangel M.; Lauda F.; Tumani H.; Mayer C.; Zeltner L.; Ziemann U.; Linker R.A.; Schwab M.; Marziniak M.; Then Bergh F.; Hofstadt-van Oy U.; Neuhaus O.; Zettl U.; Faiss J.; Wildemann B.; Paul F.; Jarius S.; Trebst C.; Kleiter I.; NEMOS (Neuromyelitis Optica Study Group). Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017,88(8),639-647","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","volume":"351","author":"Torres J.","year":"2015","unstructured":"Torres J.; Pruitt A.; Balcer L.; Galetta S.; Markowitz C.; Dahodwala N.; Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015,351(1-2),31-35","journal-title":"J Neurol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"Trebst C.","year":"2014","unstructured":"Trebst C.; Jarius S.; Berthele A.; Paul F.; Schippling S.; Wildemann B.; Borisow N.; Kleiter I.; Aktas O.; K\u00fcmpfel T.; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014,261(1),1-16","journal-title":"J Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","volume":"79","author":"Collongues N.","year":"2019","unstructured":"Collongues N.; Ayme-Dietrich E.; Monassier L.; de Seze J.; Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs 2019,79(2),125-142","journal-title":"Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","volume":"27","author":"Paul F.","year":"2018","unstructured":"Paul F.; Murphy O.; Pardo S.; Levy M.; Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018,27(3),265-271","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","volume":"13","author":"Kleiter I.","year":"2016","unstructured":"Kleiter I.; Gold R.; Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016,13(1),70-83","journal-title":"Neurotherapeutics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.187.4.461","volume":"187","author":"Alonzi T.","year":"1998","unstructured":"Alonzi T.; Fattori E.; Lazzaro D.; Costa P.; Probert L.; Kollias G.; De Benedetti F.; Poli V.; Ciliberto G.; Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998,187(4),461-468","journal-title":"J Exp Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.4049\/jimmunol.164.9.4878","volume":"164","author":"Yamamoto M.","year":"2000","unstructured":"Yamamoto M.; Yoshizaki K.; Kishimoto T.; Ito H.; IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000,164(9),4878-4882","journal-title":"J Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1917","volume":"8","author":"Gabay C.","year":"2006","unstructured":"Gabay C.; Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006,8(Suppl. 2),S3","journal-title":"Arthritis Res Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/eji.1830200134","volume":"20","author":"Gijbels K.","year":"1990","unstructured":"Gijbels K.; Van Damme J.; Proost P.; Put W.; Carton H.; Billiau A.; Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990,20(1),233-235","journal-title":"Eur J Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"Constantinescu C.S.","year":"2011","unstructured":"Constantinescu C.S.; Farooqi N.; O\u2019Brien K.; Gran B.; Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011,164(4),1079-1106","journal-title":"Br J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/ana.410360714","volume":"36","author":"Wekerle H.","year":"1994","unstructured":"Wekerle H.; Kojima K.; Lannes-Vieira J.; Lassmann H.; Linington C.; Animal models. Ann Neurol 1994,36(Suppl.),S47-S53","journal-title":"Ann Neurol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.4049\/jimmunol.139.12.4016","volume":"139","author":"Schluesener H.J.","year":"1987","unstructured":"Schluesener H.J.; Sobel R.A.; Linington C.; Weiner H.L.; A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987,139(12),4016-4021","journal-title":"J Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-7091-6284-2_10","author":"Stefferl A.","year":"2000","unstructured":"Stefferl A.; Brehm U.; Linington C.; The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 2000(58),123-133","journal-title":"J Neural Transm Suppl"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ana.20743","volume":"58","author":"Sriram S.","year":"2005","unstructured":"Sriram S.; Steiner I.; Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005,58(6),939-945","journal-title":"Ann Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Takeshita Y.","year":"2016","unstructured":"Takeshita Y.; Obermeier B.; Cotleur A.C.; Spampinato S.F.; Shimizu F.; Yamamoto E.; Sano Y.; Kryzer T.J.; Lennon V.A.; Kanda T.; Ransohoff R.M.; Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 2016,4(1)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"Chihara N.","year":"2011","unstructured":"Chihara N.; Aranami T.; Sato W.; Miyazaki Y.; Miyake S.; Okamoto T.; Ogawa M.; Toda T.; Yamamura T.; Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011,108(9),3701-3706","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cca.2014.11.004","volume":"440","author":"Chang K.H.","year":"2015","unstructured":"Chang K.H.; Ro L.S.; Lyu R.K.; Chen C.M.; Biomarkers for neuromyelitis optica. Clin Chim Acta 2015,440,64-71","journal-title":"Clin Chim Acta"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bpa.12097","volume":"24","author":"Uzawa A.","year":"2014","unstructured":"Uzawa A.; Mori M.; Kuwabara S.; Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol 2014,24(1),67-73","journal-title":"Brain Pathol"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000134","volume":"2","author":"Melamed E.","year":"2015","unstructured":"Melamed E.; Levy M.; Waters P.J.; Sato D.K.; Bennett J.L.; John G.R.; Hooper D.C.; Saiz A.; Bar-Or A.; Kim H.J.; Pandit L.; Leite M.I.; Asgari N.; Kissani N.; Hintzen R.; Marignier R.; Jarius S.; Marcelletti J.; Smith T.J.; Yeaman M.R.; Han M.H.; Aktas O.; Apiwattanakul M.; Banwell B.; Bichuetti D.; Broadley S.; Cabre P.; Chitnis T.; De Seze J.; Fujihara K.; Greenberg B.; Hellwig K.; Iorio R.; Jarius S.; Klawiter E.; Kleiter I.; Lana-Peixoto M.; Nakashima; O\u2019Connor, K.; Palace, J.; Paul, F.; Prayoonwiwat, N.; Ruprecht, K.; Stuve, O.; Tedder, T.; Tenembaum, S.; Garrahan, J.P.; Aires, B.; van Herle, K.; van Pelt, D.; Villoslada, P.; Waubant, E.; Weinshenker, B.; Wingerchuk, D.; W\u00fcrfel, J.; Zamvil, S. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015,2(4)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","volume":"16","author":"Uzawa A.","year":"2010","unstructured":"Uzawa A.; Mori M.; Arai K.; Sato Y.; Hayakawa S.; Masuda S.; Taniguchi J.; Kuwabara S.; Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010,16(12),1443-1452","journal-title":"Mult Scler"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/00207450903428970","volume":"120","author":"I\u00e7\u00f6z S.","year":"2010","unstructured":"I\u00e7\u00f6z S.; T\u00fcz\u00fcn E.; K\u00fcrt\u00fcnc\u00fc M.; Durmu\u015f H.; Mutlu M.; Eraksoy M.; Akman-Demir G.; Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010,120(1),71-75","journal-title":"Int J Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000494976","volume":"25","author":"Wei Y.","year":"2018","unstructured":"Wei Y.; Chang H.; Li X.; Wang H.; Du L.; Zhou H.; Xu W.; Ma Y.; Yin L.; Zhang X.; Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6. Neuroimmunomodulation 2018,25(4),215-224","journal-title":"Neuroimmunomodulation"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cca.2017.03.006","volume":"469","author":"Uzawa A.","year":"2017","unstructured":"Uzawa A.; Mori M.; Masuda H.; Ohtani R.; Uchida T.; Sawai S.; Kuwabara S.; Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clin Chim Acta 2017,469,144-149","journal-title":"Clin Chim Acta"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"Uzawa A.","year":"2013","unstructured":"Uzawa A.; Mori M.; Sawai S.; Masuda S.; Muto M.; Uchida T.; Ito S.; Nomura F.; Kuwabara S.; Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013,421,181-183","journal-title":"Clin Chim Acta"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000339302","volume":"19","author":"Wang H.","year":"2012","unstructured":"Wang H.; Wang K.; Zhong X.; Dai Y.; Qiu W.; Wu A.; Hu X.; Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 2012,19(5),304-308","journal-title":"Neuroimmunomodulation"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","volume":"256","author":"Uzawa A.","year":"2009","unstructured":"Uzawa A.; Mori M.; Ito M.; Uchida T.; Hayakawa S.; Masuda S.; Kuwabara S.; Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009,256(12),2082-2084","journal-title":"J Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1533-2500.2010.00367.x","volume":"10","author":"Vallejo R.","year":"2010","unstructured":"Vallejo R.; Tilley D.M.; Vogel L.; Benyamin R.; The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract 2010,10(3),167-184","journal-title":"Pain Pract"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0006-8993(00)02807-9","volume":"879","author":"Arruda J.L.","year":"2000","unstructured":"Arruda J.L.; Sweitzer S.; Rutkowski M.D.; DeLeo J.A.; Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res 2000,879(1-2),216-225","journal-title":"Brain Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fneur.2019.00341","volume":"10","author":"Serizawa K.","year":"2019","unstructured":"Serizawa K.; Tomizawa-Shinohara H.; Yasuno H.; Yogo K.; Matsumoto Y.; Anti-IL-6 Receptor antibody inhibits spontaneous pain at the pre-onset of experimental autoimmune encephalomyelitis in mice. Front Neurol 2019,10,341","journal-title":"Front Neurol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","volume":"51","author":"Strand V.","year":"2012","unstructured":"Strand V.; Burmester G.R.; Ogale S.; Devenport J.; John A.; Emery P.; Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012,51(10),1860-1869","journal-title":"Rheumatology (Oxford)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"Srirangan S.","year":"2010","unstructured":"Srirangan S.; Choy E.H.; The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010,2(5),247-256","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"Brunner H.I.","year":"2015","unstructured":"Brunner H.I.; Ruperto N.; Zuber Z.; Keane C.; Harari O.; Kenwright A.; Lu P.; Cuttica R.; Keltsev V.; Xavier R.M.; Calvo I.; Nikishina I.; Rubio-P\u00e9rez N.; Alexeeva E.; Chasnyk V.; Horneff G.; Opoka-Winiarska V.; Quartier P.; Silva C.A.; Silverman E.; Spindler A.; Baildam E.; G\u00e1mir M.L.; Martin A.; Rietschel C.; Siri D.; Smolewska E.; Lovell D.; Martini A.; De Benedetti F.; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015,74(6),1110-1117","journal-title":"Ann Rheum Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3109\/08830185.2014.938325","volume":"34","author":"Hashizume M.","year":"2015","unstructured":"Hashizume M.; Tan S.L.; Takano J.; Ohsawa K.; Hasada I.; Hanasaki A.; Ito I.; Mihara M.; Nishida K.; Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol 2015,34(3),265-279","journal-title":"Int Rev Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"Le R.Q.","year":"2018","unstructured":"Le R.Q.; Li L.; Yuan W.; Shord S.S.; Nie L.; Habtemariam B.A.; Przepiorka D.; Farrell A.T.; Pazdur R.; FDA Approval Summary: Tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018,23(8),943-947","journal-title":"Oncologist"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"Stone J.H.","year":"2017","unstructured":"Stone J.H.; Tuckwell K.; Dimonaco S.; Klearman M.; Aringer M.; Blockmans D.; Brouwer E.; Cid M.C.; Dasgupta B.; Rech J.; Salvarani C.; Schett G.; Schulze-Koops H.; Spiera R.; Unizony S.H.; Collinson N.; Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017,377(4),317-328","journal-title":"N Engl J Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/DDDT.S150580","volume":"13","author":"Biggioggero M.","year":"2018","unstructured":"Biggioggero M.; Crotti C.; Becciolini A.; Favalli E.G.; Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2018,13,57-70","journal-title":"Drug Des Devel Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","volume":"9","author":"Reichert J.M.","year":"2017","unstructured":"Reichert J.M.; Antibodies to watch in 2017. MAbs 2017,9(2),167-181","journal-title":"MAbs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","volume":"23","author":"Araki M.","year":"2013","unstructured":"Araki M.; Aranami T.; Matsuoka T.; Nakamura M.; Miyake S.; Yamamura T.; Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013,23(4),827-831","journal-title":"Mod Rheumatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"Kieseier B.C.","year":"2013","unstructured":"Kieseier B.C.; St\u00fcve O.; Dehmel T.; Goebels N.; Leussink V.I.; Mausberg A.K.; Ringelstein M.; Turowski B.; Aktas O.; Antoch G.; Hartung H.P.; Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013,70(3),390-393","journal-title":"JAMA Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-202939","author":"Lauenstein A.S.","year":"2014","unstructured":"Lauenstein A.S.; Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep, 2014 2014","journal-title":"BMJ Case Rep, 2014"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12883-014-0247-3","volume":"14","author":"Harmel J.","year":"2014","unstructured":"Harmel J.; Ringelstein M.; Ingwersen J.; Mathys C.; Goebels N.; Hartung H.P.; Jarius S.; Aktas O.; Interferon-\u03b2-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol 2014,14,247","journal-title":"BMC Neurol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1055\/s-0039-1684004","volume":"50","author":"Breu M.","year":"2019","unstructured":"Breu M.; Glatter S.; H\u00f6ftberger R.; Freilinger M.; Kircher K.; Kasprian G.; Seidl R.; Kornek B.; Two cases of pediatric aqp4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab. Neuropediatrics 2019,50(3),193-196","journal-title":"Neuropediatrics"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3109\/14397595.2013.861333","volume":"26","author":"Komai T.","year":"2016","unstructured":"Komai T.; Shoda H.; Yamaguchi K.; Sakurai K.; Shibuya M.; Kubo K.; Takahashi T.; Fujio K.; Yamamoto K.; Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol 2016,26(2),294-296","journal-title":"Mod Rheumatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.pediatrneurol.2017.05.015","volume":"73","author":"Marino A.","year":"2017","unstructured":"Marino A.; Narula S.; Lerman M.A.; First pediatric patient with neuromyelitis optica and sj\u00f6gren syndrome successfully treated with tocilizumab. Pediatr Neurol 2017,73,e5-e6","journal-title":"Pediatr Neurol"},{"key":"ref=76","author":"Capobianco M.","year":"2019","unstructured":"Capobianco M.; tocilizumab during pregnancy for neuromyelitis optica spectrum disorder: a case report. multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, england. 2019"},{"key":"ref=77","author":"Mancinelli C.","year":"2018","unstructured":"Mancinelli C.; Tocilizumab after autologous hematopoietic stem cell transplantation in refractory neuromyelitis optica: a case report. multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England. 2018"},{"key":"ref=78","year":"2017","unstructured":"meca-lallana, v. experience with tocilizumab in treatment of neuromyelitis optica. multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England. 2017"},{"key":"ref=79","author":"Meinl I.","year":"2018","unstructured":"Meinl I.; Kuempfel T.; Early relapse after rituximab initiation in a patient with neuromyelitis optica spectrum disease and side effects to subsequent tozilizumab therapy: need for further treatment options? Multiple Sclerosis Journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England 2018","journal-title":"Multiple Sclerosis Journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England"},{"key":"ref=80","author":"Siwoski M-V.","year":"2019","unstructured":"Siwoski M-V.; Lynch S.G.; Treatment Resistant Neuromyelitis Optica Responsive to Anti IL-6 Immunotherapy ACTRIMS Forum 2019 2019","journal-title":"Treatment Resistant Neuromyelitis Optica Responsive to Anti IL-6 Immunotherapy ACTRIMS Forum 2019"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"Ayzenberg I.","year":"2013","unstructured":"Ayzenberg I.; Kleiter I.; Schr\u00f6der A.; Hellwig K.; Chan A.; Yamamura T.; Gold R.; Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013,70(3),394-397","journal-title":"JAMA Neurol"},{"key":"ref=82","first-page":"30033","volume":"S0213-4853","author":"Carre\u00f3n G.E.","year":"2019","unstructured":"Carre\u00f3n G.E.; Hern\u00e1ndez C.R.; Castillo T., T.; Meca L.V.; Arocas C.V.; Iniesta M.F.; Olascoaga U.J.; Meca L.J.E.; Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia 2019,S0213-4853(19),30033-30037","journal-title":"Neurologia"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"Ringelstein M.","year":"2015","unstructured":"Ringelstein M.; Ayzenberg I.; Harmel J.; Lauenstein A.S.; Lensch E.; St\u00f6gbauer F.; Hellwig K.; Ellrichmann G.; Stettner M.; Chan A.; Hartung H.P.; Kieseier B.; Gold R.; Aktas O.; Kleiter I.; Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015,72(7),756-763","journal-title":"JAMA Neurol"},{"key":"ref=84","author":"Dalla C.G.","year":"2019","unstructured":"Dalla C.G.; Eefficacy and safety of tocilizumab for the treatment of refractory neuromyelitis optica multiple sclerosis journal; sage publications: ltd 1 olivers yard 55 city road, london ec1y 1sp, england 2019","journal-title":"Eefficacy and safety of tocilizumab for the treatment of refractory neuromyelitis optica multiple sclerosis journal; sage publications: ltd 1 olivers yard 55 city road, london ec1y 1sp, england"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101920","volume":"39","author":"Lotan I.","year":"2019","unstructured":"Lotan I.; Charlson R.W.; Ryerson L.Z.; Levy M.; Kister I.; Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2019,39","journal-title":"Mult Scler Relat Disord"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"Araki M.","year":"2014","unstructured":"Araki M.; Matsuoka T.; Miyamoto K.; Kusunoki S.; Okamoto T.; Murata M.; Miyake S.; Aranami T.; Yamamura T.; Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014,82(15),1302-1306","journal-title":"Neurology"},{"key":"ref=87","author":"Shi F-D","year":"2019","unstructured":"Shi F-D; Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): A head-to-head comparative study annals of neurology; wiley 111 river st, hoboken 07030-5774, nj usa 2019","journal-title":"Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): A head-to-head comparative study annals of neurology; wiley 111 river st, hoboken 07030-5774, nj usa"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.10.012","volume":"130","author":"Araki M.","year":"2019","unstructured":"Araki M.; Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int 2019,130","journal-title":"Neurochem Int"},{"key":"ref=89","author":"Ringelstein M.","year":"2019","unstructured":"Ringelstein M.; Long-term interleukin-6-receptor blockade in neuromyelitis optica spectrum disorder and mog associated encephalomyelitis. multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England 2019","journal-title":"multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, England"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","volume":"92","author":"Hayward-Koennecke H.","year":"2019","unstructured":"Hayward-Koennecke H.; Reindl M.; Martin R.; Schippling S.; Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology 2019,92(16),765-767","journal-title":"Neurology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.msard.2018.11.012","volume":"27","author":"Novi G.","year":"2019","unstructured":"Novi G.; Gastaldi M.; Franciotta D.; Pesce G.; Benedetti L.; Uccelli A.; Tocilizumab in MOG-antibody spectrum disorder: a case report. Mult Scler Relat Disord 2019,27,312-314","journal-title":"Mult Scler Relat Disord"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"Yamamura T.","year":"2019","unstructured":"Yamamura T.; Kleiter I.; Fujihara K.; Palace J.; Greenberg B.; Zakrzewska-Pniewska B.; Patti F.; Tsai C.P.; Saiz A.; Yamazaki H.; Kawata Y.; Wright P.; De Seze J.; Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019,381(22),2114-2124","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S43.008","volume":"92","author":"Yamamura T.","year":"2019","unstructured":"Yamamura T.; Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD) (S43.008). Neurology 2019,92(15)(Suppl.)","journal-title":"Neurology"},{"key":"ref=94","author":"Traboulsee A.","year":"2019","unstructured":"Traboulsee A.; Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebocontrolled Phase 3 clinical study. Multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, england 2019","journal-title":"Multiple sclerosis journal; sage publications: ltd 1 olivers yard, 55 city road, london ec1y 1sp, england"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"Damato V.","year":"2016","unstructured":"Damato V.; Evoli A.; Iorio R.; Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016,73(11),1342-1348","journal-title":"JAMA Neurol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"Pittock S.J.","year":"2019","unstructured":"Pittock S.J.; Berthele A.; Fujihara K.; Kim H.J.; Levy M.; Palace J.; Nakashima I.; Terzi M.; Totolyan N.; Viswanathan S.; Wang K.C.; Pace A.; Fujita K.P.; Armstrong R.; Wingerchuk D.M.; Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019,381(7),614-625","journal-title":"N Engl J Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"Cree B.A.C.","year":"2019","unstructured":"Cree B.A.C.; Bennett J.L.; Kim H.J.; Weinshenker B.G.; Pittock S.J.; Wingerchuk D.M.; Fujihara K.; Paul F.; Cutter G.R.; Marignier R.; Green A.J.; Aktas O.; Hartung H.P.; Lublin F.D.; Drappa J.; Barron G.; Madani S.; Ratchford J.N.; She D.; Cimbora D.; Katz E.; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 2019,394(10206),1352-1363","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","volume":"17","author":"Kessler R.A.","year":"2017","unstructured":"Kessler R.A.; Mealy M.A.; Jimenez-Arango J.A.; Quan C.; Paul F.; L\u00f3pez R.; Hopkins S.; Levy M.; Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Mult Scler Relat Disord 2017,17,198-201","journal-title":"Mult Scler Relat Disord"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116671","volume":"410","author":"Akaishi T.","year":"2020","unstructured":"Akaishi T.; Takahashi T.; Nakashima I.; Abe M.; Ishii T.; Aoki M.; Fujihara K.; Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci 2020,410","journal-title":"J Neurol Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"Jarius S.","year":"2012","unstructured":"Jarius S.; Ruprecht K.; Wildemann B.; Kuempfel T.; Ringelstein M.; Geis C.; Kleiter I.; Kleinschnitz C.; Berthele A.; Brettschneider J.; Hellwig K.; Hemmer B.; Linker R.A.; Lauda F.; Mayer C.A.; Tumani H.; Melms A.; Trebst C.; Stangel M.; Marziniak M.; Hoffmann F.; Schippling S.; Faiss J.H.; Neuhaus O.; Ettrich B.; Zentner C.; Guthke K.; Hofstadt-van Oy U.; Reuss R.; Pellkofer H.; Ziemann U.; Kern P.; Wandinger K.P.; Bergh F.T.; Boettcher T.; Langel S.; Liebetrau M.; Rommer P.S.; Niehaus S.; M\u00fcnch C.; Winkelmann A.; Zettl U.; U.K.; Metz, I.; Veauthier, C.; Sieb, J.P.; Wilke, C.; Hartung, H.P.; Aktas, O.; Paul, F. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012,9,14","journal-title":"J Neuroinflammation"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/ene.12058","volume":"20","author":"K\u0131yat-Atamer A.","year":"2013","unstructured":"K\u0131yat-Atamer A.; Ekizo\u011flu E.; T\u00fcz\u00fcn E.; K\u00fcrt\u00fcnc\u00fc M.; Shugaiv E.; Akman-Demir G.; Eraksoy M.; Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. Eur J Neurol 2013,20(5),781-787","journal-title":"Eur J Neurol"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181462\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/181462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T22:58:05Z","timestamp":1722812285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181462\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200429010825","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}